AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 71 min read$TEM

Tempus (TEM) Expands Multi‑Year Deal With Moderna and Merck

Tempus extended its multi-year partnership with Moderna and Merck to support the potential commercialization of V940/mRNA-4157 with KEYTRUDA, including sample logistics and NGS services. Financial details were not disclosed.

Original reporting
tradingview.com
Published Oct 7, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tempus (TEM) Expands Multi‑Year Deal With Moderna and Merck — source image
Source · tradingview.com
Decision brief

The 30-second read

$TEMBullishLow
01

Why it matters

The expanded collaboration could increase Tempus' service revenue if the vaccine progresses to market, but the impact is contingent on regulatory approval and commercial uptake.

02

Market read

The deal underscores growing integration of genomic data services with immunotherapy development, potentially benefiting the precision oncology market.

03

What to watch

Regulatory approval of the vaccine candidate remains uncertain, which could limit upside.

Relevance 5/10Novelty 5/10Timing: today

Background

Tempus provides genomic sequencing and data analytics for cancer treatment; Moderna and Merck are developing a personalized cancer vaccine (V940/mRNA‑4157) paired with KEYTRUDA.

Company-level read

Ticker impact

$TEMBullishMedium confidence
Context

Tempus announced an expanded multi‑year collaboration with Moderna and Merck to support commercialization of a cancer vaccine candidate.

Expected impact

likely upward pressure as the market prices in expanded commercial services.

Evidence & confidence

While financial terms are undisclosed, the addition of two major pharma partners signals growth potential for Tempus' NGS services.

Market effects

Sector

strengthens the oncology diagnostics and personalized medicine sector.

Regional

U.S. biotech market may see modest uplift.

Global

Highlights continued collaboration between U.S. diagnostics firms and large pharma.

Counterpoint

What could challenge this read

Without disclosed financial terms, the deal may not materially affect Tempus' near‑term earnings.

Key entities

  • Company
    Tempus

    U.S. biotech firm offering genomic sequencing services.

  • Company
    Moderna

    Pharmaceutical company developing mRNA‑based therapies.

  • Company
    Merck

    Global pharma company co‑developing the cancer vaccine.

Read at source← All news

Related articles

OCT 7
$MRKHigh

Dutch court orders Merck to halt Keytruda sales in Europe

A Dutch court ruled in favor of Halozyme Therapeutics, ordering Merck & Co. to halt sales of injectable Keytruda in eight European markets. The court found Merck infringed Halozyme's patent for a rapid drug delivery technology. Merck disputes the ruling and is reviewing its options. Keytruda SC is crucial for Merck's growth as patents on its original version expire later this decade.

investing.com2 min
OCT 7
$MRNAHigh

MRNA Jumps As Nasdaq-100 Inclusion And Cancer Pipeline Shift Momentum

Moderna Inc. (MRNA) shares rose 4.78% on October 7, 2026, driven by positive mRNA pipeline data and upcoming inclusion in the Nasdaq-100 index. The company reported quarterly revenue of $1.92B, but with significant losses. Traders are watching MRNA for its potential as a growth platform with catalysts like the index inclusion and cancer vaccine developments.

stockstotrade.com3 min
OCT 7
$MRNAHighAI 8/10

MRNA Stock Jumps As Nasdaq-100 Inclusion Ignites Momentum

Moderna Inc. (MRNA) stock rose 4.82% after being added to the Nasdaq-100 index. The company reported a net loss of $782M but has strong cash reserves. Positive data for its cancer vaccine and a new COO appointment also influenced trading. MRNA's stock has been volatile, with a recent uptrend and a 6-7% drop on the management change news.

timothysykes.com2 min
OCT 7
$TEMMed

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure - Tempus AI (NASDAQ:TEM)

Tempus Inc. (TEM) expanded its collaboration with Moderna (MRNA) and Merck (MRK) to support the development of a cancer vaccine. Tempus will manage sample collection and provide NGS services. The company also partnered with Bristol Myers Squibb (BMY) to improve clinical trial design. Additionally, Tempus acquired Personalis (PSNL) for $1.5 billion to enhance cancer monitoring. TEM shares were down 1.94% to $70.58 at the time of publication.

benzinga.com3 min